|
|
 |
|
Viewing report
|
|
|
|
Global Vaccines Market
Frost & Sullivan, Dec 2009, Pages: 84
This research service covers the global vaccines market from 2005-2015. Included is discussion of issues such as key trends, products, challenges, drivers, and competitive structure. Revenue forecasts are also presented for the global market, North America, Europe, and Rest-of-World, with geographic and company market shares at the global level. Vaccines as a value of total revenues for key companies in the market are also assessed, Quarter-by-Quarter HPV vaccine growth rate trends by region, as well as weighting of vaccines revenues as a percent of regional revenues for the pharma industry. The pipeline for vaccines is also presented by clinical trial phase, as well as selected commentary for key disease areas.
Scope and Segmentation
The global vaccines market is comprised of a variety of vaccines for the prevention of diseases in adults, adolescents, and children. For the purposes of this research service, Frost & Sullivan has divided this market into the following regions: North America, which accounts for the United States and Canada, Europe, and Rest-of-World (ROW), which is considered to be countries covered by the Global Alliance for Vaccines and Immunization (GAVI) in Asia, Latin America, and Africa. Developed markets are considered to be Europe and North America, emerging markets refers to regions such as India, China, and Brazil, and under-developed markets refers to Africa.
A pipeline analysis of select novel advances in vaccine research has also been included in this research service and is for 2009. The base year for this research service is 2008, and the forecast is provided from 2005 to 2015. Compound Annual Growth Rate (CAGR) is presented for the period 2008-2015 unless otherwise indicated.
Research Methodology
For purpose of this research service the global vaccines markets include revenues derived from the sale of vaccines. The research for this study was conducted through secondary and primary research. Secondary research included data from multiple sources including company websites and scientific journals. Current market size figures were derived through primary research which included interviews with industry participants in positions such as CEOs, vice presidents of marketing, global marketing analysts, and investor relations. Base year revenues were derived through direct interviews with representatives of major industry participants and from their financial filings, and the CAGR has been estimated through primary and secondary research.
Revenues for the base year and historical period have been determined by evaluating the vaccine market's expenditures globally. Once the total value is validated, it is then segmented based on the geographical region and product types. It is impossible to take into account unexpected shifts in demand that emerge as a result of unforeseen price, production problems, seasonal demand or regulatory changes, consumer/end user characteristic changes, or any other drastic future events that occur after the research process is complete. These cannot be totally accounted for in this study.
Market Overview
Overall, the pharmaceutical and biotechnology industry is in a state of transition. Reorganization, M&A, consolidation, and portfolio changes are being evaluated in order to maintain growth centers in the face of a myriad of serious challenges. With this, companies are interested in vaccines and vaccine technologies as a possible area to provide them with revenue potential for the future. This coupled with critical global public health issues tied to vaccines as well as crisis issues such as H1N1—Swine flu, keeps the vaccine area as one of the key industry focal points. Additionally, as Big Pharma continues to transition to more of a 'Big Biopharma' model, vaccines is an area of increasing potential value and visibility to the top tier companies.
While the revenue generated by the global vaccines market is relatively small when compared to total pharmaceutical sales, the market has been growing at an impressive rate and is expected to continue to do so over the period from 2009 to 2015. This growth will depend on the success and penetration of vaccines into three major markets.
- Developed Markets - The introduction of new products, innovative delivery technologies, and improved vaccination coverage across the market is the key to success of these markets. The North American and European markets are classified as developed markets.
- Emerging Markets - These are emerging as the backbone for the growth of global vaccines market. The focus of these markets is on the stricter enforcement of intellectual property rights of the middle class and increased efforts by the government to focus on public vaccination campaigns. The emerging markets include the fast developing economies in Asia and Latin America, such as India, China, and Brazil.
- Developing and Underdeveloped Markets1These markets being given a high level of importance by the World Health Organization (WHO) and Pan-American Health Organization (PAHO). The funding for vaccination programs in these markets is drawn from developed markets, who indirectly subsidize the cost of vaccines. The emergence of various charity funds, which have started to support vaccination programs in a big way, have been received well in these markets.
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
Human Vaccines - Global Strategic Business Report
The Infectious Disease Vaccine Pipeline - A Competitive Review
Pediatric Vaccines Market to 2017- Strategic Focus on Partnering as Licensing and Co-Development Accounted for 69% of Deal-Making Activity from 2004-2011
Adult and Adolescent Vaccines Market to 2017 - Partnerships Increase as Licensing and Co-Development Account for 73% of all Deal-Making Activity in 2010
Emerging Cancer Vaccines Market to 2017 - Novel, First-In-Class Vaccines in Phase II and Phase III Pipeline to Shape the Future Cancer Vaccines Market
The Future of Global Vaccines - Market Forecasts to 2016, Stockpile Analysis, Competitive Benchmarking and Pipeline Analysis
Strategic Overview of the Infectious Disease Vaccine
Travel Vaccines Market to 2017 - Growth in International Travel and Higher Incidences of Infectious Diseases in Emerging Economies to Drive the Market
Manufacturing of Vaccines - Cell Culture Technology Gradually Replacing Egg-Based Manufacturing
Vaccines Review and Outlook 2010
|
|
|
|
